ADXS-HPV Designated Orphan Drug for HPV-Associated Anal Cancer – Monthly Prescribing Reference

ADXS-HPV Designated Orphan Drug for HPV-Associated Anal Cancer
Monthly Prescribing Reference
Advaxis announced that its lead drug candidate ADXS-HPV has been granted Orphan Drug Designation by the FDA for the treatment of human papillomavirus (HPV)-associated anal cancer. ADXS-HPV is an immunotherapy that is designed to target cells 

and more »

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *